Advaxis

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Its lead candidates are the oral gamma secretase inhibitor, AL102, for desmoid tumors, and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. The company was founded on June 5, 1987 and is headquartered in Monmouth Junction, NJ.

Non-dilutive capital will support advancement of ADXS-HOT neoantigen program Non-dilutive capital will support advancement of ADXS-HOT neoantigen program

UPDATE - Advaxis Announces Achievement of Second Milestone Under ADXS-HER2 Licensing Agreement with OS Therapies

Non-dilutive capital to support advancement of ADXS-HOT neoantigen program Non-dilutive capital to support advancement of ADXS-HOT neoantigen program

Advaxis Announces Receipt of Second Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies

Advaxis, Inc. (NASDAQ: ADXS), CEO Ken Berlin presented at the Benzinga Biotech Small-Cap Conference on March 24, 2021. Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, is making new waves as it takes definitive steps to prove that the company is “no longer your grandfather's Advaxis,” according to company CEO Ken Berlin.

ADVAXIS MAKING BOLD STEPS IN NEW CANCER STUDIES AND AGREEMENT WITH COLUMBIA UNIVERSITY

PRINCETON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it has entered into definitive agreements with two healthcare-focused, institutional investors for the purchase of (i) 17,577,400 shares of common stock , (ii) 7,671,937 pre-funded warrants (the “Pre-Funded Warrants”) to purchase 7,671,937 shares of common stock and (iii) registered common share purchase warrants to purchase 11,244,135 shares of common stock. The Company has also agreed to issue to the investors, in a concurrent private placement, unregistered common share purchase warrants to purchase 14,005,202 shares of the Company's common stock. Each share of common stock and accompanying common share purchase warrant are being sold together at a combined offering price of $0.7921, and each Pre-funded Warrant and accompanying common warrant are being sold together at a combined offering price of $0.7911, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules. The Pre-Funded Warrants are immediately exercisable, at an exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The registered common share purchase warrants will have an exercise price of $0.70 per share, will be immediately exercisable, and will expire five (5) years from the date of issuance. The unregistered common share purchase warrants will have an exercise price of $0.70 per share, will be exercisable fourteen days after the Company increases its authorized share capital, and will expire five (5) years from their initial exercise date (collectively, the “Offering”).

Advaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a pharmacodynamic biomarker in T cells during PD-1 blockade

Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting

PRINCETON, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Precision for Medicine, a specialized services company supporting next generation approaches to drug development and commercialization, today announce that they will present data on a) the development of a novel flow immunophenotyping assay to accurately evaluate total PD-1 expression as a pharmacodynamic biomarker during PD-1 blockade treatment with pembrolizumab and b) the correlation of changes in T cell populations with the clinical activity observed in the ongoing ADXS-503 clinical trial, in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021, taking place virtually from April 10-15, 2021.

Advaxis to Present at the American Association for Cancer Research (AACR) 2021 Annual Meeting

Enrolling strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors

Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update

Non-dilutive capital strengthens balance sheet to further advance ADXS-HOT neoantigen program Non-dilutive capital strengthens balance sheet to further advance ADXS-HOT neoantigen program

Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies

PRINCETON, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it received a positive determination from the Nasdaq Stock Market granting approval of the Company's request to transfer its listing to the Nasdaq Capital Market from the Nasdaq Global Select Market. The Company's securities will begin trading on the Nasdaq Capital Market effective at the start of trading on December 24, 2020. The Company's shares will continue to trade on Nasdaq under the symbol “ADXS.”

Advaxis Announces Listing Transfer to Nasdaq Capital Market and Additional 180-day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

New York, New York--(Newsfile Corp. - December 16, 2020) - Levi & Korsinsky announces it has commenced an investigation of Advaxis, Inc. (NASDAQ: ADXS) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/advaxis-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Advaxis, Inc.- ADXS

PRINCETON, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the closing of an underwritten public offering of 26,666,666 shares of common stock and warrants to purchase up to 13,333,333 shares of common stock, along with an additional 3,999,999 shares of common stock and 1,999,999 warrants pursuant to the full exercise of the underwriters' option. The shares of common stock and warrants were sold together at a combined public offering price of $0.30 per share for total gross proceeds of approximately $9.2 million, before underwriting commissions and estimated expenses.

Advaxis, Inc. Announces Closing of $9.2 Million Public Offering

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile failures like hedge funds' 2018 losses in Facebook and Apple. Let's take a closer look at what the funds we track think about Advaxis, Inc. (NASDAQ:ADXS) in this article.

Here is What Hedge Funds Think About Advaxis, Inc. (ADXS)

Alnylam Pharmaceuticals

Arrowhead Pharmaceuticals

Alnylam Pharmaceuticals (NASDAQ: ALNY) shares are trading higher on Tuesday after the company announced its OXLUMO injection has received FDA approval for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs.

Why These 3 Pharma Stocks Are Moving Today

PRINCETON, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of (i) 26,666,666 shares of common stock and warrants to purchase up to 13,333,333 shares of common stock. The shares of common stock and warrants are being sold together at a combined public offering price of $0.30 per share. The warrants will have an exercise price of $0.35 per share, will be immediately exercisable and will expire five years from the date of issuance. The Company has granted the underwriters a 30-day option to purchase up to an additional 3,999,999 shares of common stock and/or 1,999,999 warrants to cover over-allotments, if any.

Advaxis, Inc. Announces Pricing of $8 Million Public Offering

PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock and/or purchase warrants to purchase additional shares of common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the size or terms of the proposed offering.

Advaxis, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock

Disease control rate of 67% and overall response rate of 17% in first six evaluable patients with immediate prior progression on KEYTRUDA ®

Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

PRINCETON, N.J., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Advaxis , Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it will present an ePoster at the 35th Annual Meeting of the Society for Immunology of Cancer (SITC 2020) to be held virtually November 9-14, 2020.

Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020

PRINCETON, N.J., Sept.  29, 2020  (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that its Board of Directors has approved the adoption of a limited duration stockholder rights plan and declared a dividend distribution of one right for each outstanding share of common stock. The record date for such dividend distribution is October 12, 2020. The rights plan expires, without any further action being required to be taken by the Company’s Board of Directors, on September 28, 2021.

Advaxis, Inc. Adopts Limited Duration Stockholder Rights Plan

Strategic transition to Investigator sponsored IND from previously announced Advaxis sponsored IND

Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer

Strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and or restore sensitivity to checkpoint inhibitors

Advaxis Reports Third Quarter Ended July 31, 2020 Financial Results and Provides a Business Update

PRINCETON, N.J., Sept.  04, 2020  (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced that Molly Henderson, Executive Vice President and Chief Financial Officer, has resigned effective September 25, 2020 to pursue another business opportunity. Kenneth A. Berlin, Advaxis’ President and Chief Executive Officer, will serve as interim Chief Financial Officer until a new Chief Financial Officer is appointed.

Advaxis Announces Resignation of Chief Financial Officer

PRINCETON, N.J., Aug.  27, 2020  (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will present a corporate overview at the LD Micro 500 Virtual Conference, being held virtually September 1 – 4, 2020.

Advaxis to Present Corporate Overview at the LD Micro 500 Virtual Conference

PRINCETON, N.J., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced that it has entered into a common stock purchase agreement for up to $20 million with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor. Upon execution of the purchase agreement, Lincoln Park made an initial purchase of $2 million of common stock at $0.57 per share.

Advaxis Announces Common Stock Purchase Agreement for up to $20 Million with Lincoln Park Capital

PRINCETON, N.J., June  23, 2020  (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will be featured in a webinar, “Grand Rounds: A Webinar in Biotech and Specialty Pharma,” hosted by James Molloy, Managing Director of Equity Research, Biotechnology and Specialty Pharmaceuticals at Alliance Global Partners, on Monday, June 29, 2020.

Advaxis to be Featured in “Grand Rounds: a Webinar in Biotech and Specialty Pharma,” Hosted by Alliance Global Partners

Advaxis, Inc. (ADXS) CEO Ken Berlin on Q2 2020 Results - Earnings Call Transcript

News for Advaxis Stock (ADXS)